Watch DSGN. Know when insiders buy.
One email the day a filing lands. Free.
DSGN
Design Therapeutics, Inc.
14.63
−0.17 −1.15%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
51
WATCH · shorts 51
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $915.6MP/E —DIV YIELD —FCF YIELD -6.02%REV TTM $0NET INCOME −$70.8MNET CASH —52W 5.53 – 15.94SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$22.2M | −$20.2M | — | -0.32 | −$15.5M | $21K | −$15.5M | Aug 3 |
| Q1 2026 · Mar 31 | $0 | — | — | −$19.7M | −$17.6M | — | -0.29 | −$16.4M | $0 | −$16.4M | Apr 28 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$18.2M | −$16M | — | -0.27 | −$12M | $34K | −$12M | Mar 9 |
| Q3 2025 · Sep 30 | $0 | — | — | −$19.3M | −$17M | — | -0.30 | −$11.2M | $0 | −$11.2M | Nov 5 |
| Q2 2025 · Jun 30 | $0 | — | — | −$21.6M | −$19.1M | — | -0.34 | −$14.4M | $87K | −$14.5M | Aug 3 |
| Q1 2025 · Mar 31 | $0 | — | — | −$20.4M | −$17.7M | — | -0.31 | −$16.8M | $72K | −$16.9M | Apr 28 |
| Q4 2024 · Dec 31derived | — | — | — | −$16.7M | −$13.7M | — | -0.24 | −$9.9M | $0 | −$9.9M | Mar 9 |
| Q3 2024 · Sep 30 | — | — | — | −$16.2M | −$13M | — | -0.23 | −$9.5M | −$16K | −$9.5M | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$15M | −$11.8M | — | -0.21 | −$11.3M | $161K | −$11.4M | Aug 7 |
| Q1 2024 · Mar 31 | — | — | — | −$14.4M | −$11.1M | — | -0.20 | −$12.4M | $195K | −$12.6M | May 7 |
| Q4 2023 · Dec 31derived | — | — | — | −$15.1M | −$11.8M | — | -0.21 | −$12.8M | $27K | −$12.8M | Mar 10 |
| Q3 2023 · Sep 30 | — | — | — | −$18.8M | −$15.8M | — | -0.28 | −$14.5M | $53K | −$14.6M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$79.5M | −$69.8M | — | -1.22 | −$54.4M | $193K | −$54.6M | — | — |
| FY2024 · to Dec 31 | $0 | — | −$62.4M | −$49.6M | — | -0.88 | −$43.1M | $340K | −$43.4M | — | — |
| FY2023 · to Dec 31 | — | — | −$78.2M | −$66.9M | — | -1.19 | −$58.6M | $256K | −$58.8M | — | — |
| FY2022 · to Dec 31 | — | — | −$67.6M | −$63.3M | — | -1.14 | −$51.3M | $918K | −$52.2M | — | — |
| FY2021 · to Dec 31 | — | — | −$35.8M | −$35.5M | — | -0.77 | −$29.4M | $1.5M | −$30.9M | — | — |
| FY2020 · to Dec 31 | $226K | — | −$8.3M | −$8.3M | -3663.7% | -0.52 | −$8.7M | $76K | −$8.7M | — | — |
Every number comes from Design Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.